<?xml version="1.0" encoding="UTF-8"?>
<p>The list of experimental drugs against SARS-CoV-2 has been continuously increasing with the emergence of new data on the structure and pathogenic mechanisms of the new virus. Most of the current therapeutic data has been extrapolated from the research performed on either SARS-CoV or murine hepatitis virus (MHV), a prototypic member of the CoV family (
 <xref rid="B32" ref-type="bibr">Fung et al., 2020</xref>). The available therapeutic agents target the pathogenic steps of infection (viral entry or post-entry steps) as well as the unbalance of the immune response (
 <xref ref-type="fig" rid="f1">
  <bold>Figure 1</bold>
 </xref>).
</p>
